TME Therapeutics Inc.

TME Therapeutics Inc.

TARGETING TUMOR MICROENVIRONMENT

TARGETING TUMOR MICROENVIRONMENT

About Us

Research and development

News

Latest News

2023.6.2

Results from preclinical study were presented by Dr. Juanjuan Ye at American Society of Clinical Oncology (ASCO) annual meeting 2023.
Title: Effect of locoregional injection of RNA oligonucleotide targeting carbohydrate sulfotransferase 15 on both tumoral and lymph node MDSCs and T cell infiltration in pancreatic tumor in mice.

https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.e16310?af=R


2023.5.30

Results from preclinical study were published by Dr. Juanjuan Ye in European Journal of Immunology.

Title: Silencing of tumoral carbohydrate sulfotransferase 15 reactivates lymph node pancreatic cancer T cells in mice.

https://onlinelibrary.wiley.com/journal/15214141
https://pubmed.ncbi.nlm.nih.gov/37248998/


2022.11.18

The results from Phase 1/2a clinical study of STNM01 as a second-line therapy for unresectable pancreatic cancer were published in the LANCET eClinicalMedicine.

Fujisawa T et al. STNM01, the RNA oligonucleotide targeting carbohydrate sulfotransferase 15, as second-line therapy for chemotherapy-refractory patients with unresectable pancreatic cancer: An open label, phase I/IIa trial. The LANCET eClinicalMedicine 2023;55: 101731

https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(22)00461-8/fulltext


2022.6.2

Final results from Phase 1/2a clinical study of STNM01 as a second-line therapy for unresectable pancreatic cancer were presented by Dr. Tsuchiya at American Society of Clinical Oncology (ASCO) annual meeting 2022.

https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.4144


2022.6.2

Results from preclinical study were presented by Dr. Ye at American Society of Clinical Oncology (ASCO) annual meeting 2022.
Title: Effect of silencing tumoral carbohydrate sulfotransferase 15 on T cells in a murine model of pancreatic cancer.

https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.e16241


2022.5.22

Results from preclinical study were presented by Dr. Ye at Digestive Disease Week (DDW) annual meeting 2022.
Title: Silencing of tumoral carbohydrate sulfotransferase 15 augments tumor-infiltrating T cells with boosted lymph node T cell priming in a murine model of pancreatic cancer

SILENCING OF TUMORAL CARBOHYDRATE SULFOTRANSFERASE 15 AUGMENTS…. DDW ePoster Library. Ye J. May 22 2022; 354739


2022.5.21

Final results from Phase 1/2a clinical study of STNM01 as a second-line therapy for unresectable pancreatic cancer were presented by Dr. Tanisaka at Digestive Disease Week (DDW) annual meeting 2022.
Title: Locoregional injection of the RNA oligonucleotide targeting carbohydrate sulfotransferase 15 is able to accelerate tumor-infiltrating T cells in patients with unresectable pancreatic cancer, refractory to first-line chemotherapy

LOCOREGIONAL INJECTION OF THE RNA OLIGONUCLEOTIDE TARGETING…. DDW ePoster Library. Tanisaka Y. May 21 2022; 352839